We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
400 FAQs on Good Clinical Practice
Product News

400 FAQs on Good Clinical Practice

400 FAQs on Good Clinical Practice
Product News

400 FAQs on Good Clinical Practice


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "400 FAQs on Good Clinical Practice"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Recommended reading for new recruits to the pharmaceutical business this month is Good Clinical Practice, a pocket guide to Good Clinical Practice requirements in drug, biologics and device clinical trials. 

The pocket book guide is presented in question and answer format and covers 400 frequently asked questions about the conduct of clinical trials.  The recommendation comes from online pharma business bookshop, Piribo Ltd.

In the wake of the unprecedented adverse reactions experienced by all six triallists given the new TeGenero investigational drug this month, there has inevitably been considerable conjecture about the causes of the events in this trial. This book is an accessible introduction to the regulations governing clinical trials.

There are over 60 companies currently engaged in the development of drugs based on monoclonal antibodies, which was the class of drug involved in this trial. Six lead drugs are in Phase III and six in Phase II.

Further titles of possible interest to R&D scientists who might want to update on clinical trials in this area is New Directions in Monoclonal Antibodies, and for the latest strategies using conjugated or chimeric MAbs as anticancer therapies, there is Improved Monoclonals On The Rise, one of nearly 100 books and industry reports available form Piribo on the subject.

Advertisement